Hoth Therapeutics HOTH 深 沪
等待开盘 11-03 09:30:00 美东时间
1.42
+0.060
+4.41%
华盛通- 最 高1.42
- 今 开1.36
- 成交量 21.27万股
- 最 低 1.36
- 昨 收 1.36
- 总市值 1882.78万
- 52周最高 3.80
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 0.6554
- 委 比 -93.25%
- 总股本 1325.90万
- 历史最高 347.00
- 量 比 0.53
- 振 幅 4.41%
- 历史最低 0.58
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Hoth Therapeutics shares are trading higher after the company announced FDA Orphan Drug designation and preclinical data for HT-KIT in rare C-KIT-driven cancers
Hoth Therapeutics shares are trading higher after the company announced FDA Orp...
10-21 20:28
Hoth Therapeutics Prepares Presentation on October 17, 2025
Hoth Therapeutics ( ($HOTH) ) has shared an update. Hoth Therapeutics announced...
10-18 04:50
Hoth Therapeutics Expands Its AI Initiative Through Nvidia AI Enterprise Subscription License
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling
10-08 22:24
Hoth Therapeutics To Present HT-001 And HT-KIT Oncology Programs At BIO-Europe 2025
Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology programtargeting KIT-driven tumorsNEW YORK, Oct. 7, 2025 /PRNewswire/
10-07 20:00
Hoth Therapeutics Expands Intellectual Property Portfolio For HT-001 With New U.S. Provisional Patent Filings Covering Novel Dermatological Indications
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address
09-24 20:16
Hoth Therapeutics Faces Digital Asset Industry Challenges
Hoth Therapeutics ( ($HOTH) ) has provided an announcement. The digital assets ...
09-12 20:48
Hoth Therapeutics Submits CTA To EMA To Expand Ongoing Phase II Trial Of HT-001, Topical Therapeutic For Skin Toxicities Associated With EGFRi
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing
09-10 20:32
Hoth Therapeutics shares are trading higher after the company reported its antisense therapy demonstrated efficacy against KIT-driven cancers.
Hoth Therapeutics shares are trading higher after the company reported its anti...
09-02 20:22
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
Hoth Therapeutics reported strong preclinical efficacy and safety data for HT-KIT, a precision antisense therapy targeting KIT-driven cancers.
09-02 19:46
Top 5 Biotech Stocks With Strong Momentum
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
08-28 19:19
